Ghrelin regulates GLP-1 production through mTOR signaling in L cells

Molecular and Cellular Endocrinology

Volumn 416, Issue , 2015, Pages 9-18

  Xu, Geyang ^a   Hong, Xiaosi ^a   Tang, Hong ^b   Jiang, Sushi ^a   Liu, Fenting ^a   Shen, Zhemin ^a   Li, Ziru ^c   Zhang, Weizhen ^b,c  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b Shenzhen University School of Medicine   (China)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Enteroendocrine L cells; Ghrelin; GHSR1a; GLP 1; Incretin; MTORC1

Indexed keywords

GHRELIN; GHRELIN RECEPTOR; GLUCAGON LIKE PEPTIDE 1; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PROGLUCAGON; SMALL INTERFERING RNA; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASING HEXAPEPTIDE; INCRETIN; INSULIN; MTOR PROTEIN, MOUSE; OLIGOPEPTIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENTEROENDOCRINE CELL; ENTEROENDOCRINE L CELL; ENZYME INHIBITION; HORMONE ACTION; HORMONE RELEASE; HORMONE SYNTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; ILEUM; KNOCKOUT MOUSE; METABOLISM; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; BLOOD GLUCOSE; CELL LINE, TUMOR; ENTEROENDOCRINE CELLS; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; ILEUM; INCRETINS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGOPEPTIDES; RECEPTORS, GHRELIN; TOR SERINE-THREONINE KINASES;

EID: 84943662382     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.08.016     Document Type: Article

References (32)

1. Ahren B., Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res. 2004, 36(11-12):867-876.
2. Albert V., Hall M.N. mTOR signaling in cellular and organismal energetics. Curr. Opin. Cell Biol. 2015, 33:55-66.
3. Anini Y., Brubaker P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003, 52(2):252-259.
4. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):2632-2637.
5. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157.
6. Brown J.C., Dryburgh J.R., Ross S.A., Dupre J. Identification and actions of gastric inhibitory polypeptide. Recent Prog. Horm. Res. 1975, 31:487-532.
7. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27(11):2628-2635.
8. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50(8):1714-1719.
9. Damholt A.B., Buchan A.M., Kofod H. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology 1998, 139(4):2085-2091.
10. Date Y., Kojima M., Hosoda H., Sawaguchi A., Mondal M.S., Suganuma T., et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000, 141(11):4255-4261.
11. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80(3):952-957.
12. Degn K.B., Juhl C.B., Sturis J., Jakobsen G., Brock B., Chandramouli V., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53(5):1187-1194.
13. 2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 2004, 53(12):3142-3151.
14. Dezaki K., Sone H., Koizumi M., Nakata M., Kakei M., Nagai H., et al. Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance. Diabetes 2006, 55(12):3486-3493.
15. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26(10):2929-2940.
16. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3(3):153-165.
17. Egido E.M., Rodriguez-Gallardo J., Silvestre R.A., Marco J. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur. J. Endocrinol. 2002, 146(2):241-244.
18. Gagnon J., Baggio L.L., Drucker D.J., Brubaker P.L. Ghrelin is a novel regulator of GLP-1 secretion. Diabetes 2015, 64(5):1513-1521.
19. Jin T., Drucker D.J. The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription. Mol. Endocrinol. 1995, 9(10):1306-1320.
20. Lim G.E., Huang G.J., Flora N., LeRoith D., Rhodes C.J., Brubaker P.L. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology 2009, 150(2):580-591.
21. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 214(3):829-835.
22. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987, 79(2):616-619.
23. Mortensen K., Christensen L.L., Holst J.J., Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 2003, 114(2-3):189-196.
24. Muller T.D., Nogueiras R., Andermann M.L., Andrews Z.B., Anker S.D., Argente J., et al. Ghrelin. Mol. Metab. 2015, 4(6):437-460.
25. Pusztai P., Sarman B., Ruzicska E., Toke J., Racz K., Somogyi A., et al. Ghrelin: a new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diabetes Metab. Res. Rev. 2008, 24(5):343-352.
26. Sun Y., Asnicar M., Saha P.K., Chan L., Smith R.G. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 2006, 3(5):379-386.
27. Tolhurst G., Reimann F., Gribble F.M. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 2009, 587(pt1):28-32.
28. Wang Y., Nishi M., Doi A., Shono T., Furukawa Y., Shimada T., et al. Ghrelin inhibits insulin secretion through the AMPK-UCP2 pathway in beta cells. FEBS. Lett. 2010, 584(8):1503-1508.
29. Xu G., Wang Z., Li Y., Li Z., Tang H., Zhao J., et al. Ghrelin contributes to derangements of glucose metabolism induced by rapamycin in mice. Diabetologia 2012, 55(6):1813-1823.
30. Xu G., Li Z., Ding L., Tang H., Guo S., Liang H., et al. Intestinal mTOR regulates GLP-1 production in mouse L cells. Diabetologia 2015, 58(8):1887-1897.
31. Zhang W., Zhao L., Mulholland M.W. Ghrelin stimulates myocyte development. Cell Physiol. Biochem. 2007, 20(5):659-664.
32. Zhang X., Li W., Li P., Chang M., Huang X., Li Q., et al. Intraportal infusion of ghrelin could inhibit glucose-stimulated GLP-1 secretion by enteric neural net in Wistar rat. Biomed. Res. Int 2014, Article ID 923564.